Vectura Group
Inhalation is our primary focus. Whether you’re working on small or large molecules, for a small biotech or large pharmaceutical company, we are here to support you at every stage of the development pathway.
Trending Articles
Related Content
Drug Delivery
Optimising dry powder inhaler programmes through formulation
The use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action. However, direct delivery to the lung is also a quick and efficient way of administering non-respiratory drugs systemically without have to wait for them to be absorbed through the gut
Ingredients
Accelerating excipient development for inhalable dosage forms with QbD
Whether they are simply giving an oral dose the bulk it needs to permit handling and swallowing or performing more complex functions that enable successful delivery and product performance, excipients are critical components of all drug formulations, explains Iain Davidson, Senior Manager, Pharmaceutical Development, Vectura